Key takeaways
Lamivudine (Epivir) and Triumeq (abacavir/dolutegravir/lamivudine) are both used to treat HIV, but they have some key differences. Lamivudine (Epivir) is a nucleoside reverse transcriptase inhibitor (NRTI) that can also treat hepatitis B (HBV), while Triumeq is a combination of three medications: abacavir, dolutegravir, and lamivudine. Triumeq is only for HIV treatment and includes an integrase inhibitor (dolutegravir) along with two NRTIs. Lamivudine (Epivir) can be taken once or twice daily, whereas Triumeq is taken once daily. Triumeq requires a genetic test before starting to check for a risk of serious allergic reactions, while lamivudine (Epivir) does not. Additionally, Triumeq is not recommended for people with severe liver problems, and it interacts with many other medications, unlike lamivudine (Epivir), which has fewer interactions. Both medications can cause serious side effects, including liver problems and lactic acidosis, but Triumeq also has a risk of severe allergic reactions due to abacavir.
